Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway

Xue Wu 1, Ping Liu 1, Haijun Zhang 1, Yuan Li 2, Jumah Masoud Mohammad Salmani 1, Fei Wang 1, Ke Yang 3, Rong Fu 4, Zhewei Chen 1 and Baoan Chen 1*

Abstract

Background: Wogonin is an encouraging choice for clinical use owing to its potent anti-tumor and anti-inflammatory effects with the high safety profile. However, wogonin for targeted therapy of lymphoma was not well addressed. In this study, we focused on its anticancer effect alongside with the underlying mechanisms for targeted therapy in EBV-positive lymphoma. This will facilitate its introduction to clinical use, which is planned in the near future.

Methods: Cell proliferation was studied by CCK8. Flow cytometry was used to analyze the apoptosis and the cycle arrest of cells. Further, we also used immunofluorescent staining to detect the morphologic changes of the apoptotic cells. The expression of LMP1/miR-155/p65/pp65/PU.1 was evaluated by quantitative real-time PCR (qRT-PCR) and western blot, while that of NF-κB was analyzed by EMSA. At last, immunohistochemical staining was applied to assess the expression of target proteins and relevant molecules.

Results: In vitro, wogonin induced the apoptosis of Raji cells by downregulating the expression of NF-κB through LMP1/miR-155/NF-κB/PU.1 pathway, which was in a dose and time-dependent manner. In vivo, wogonin could suppress tumor growth, associated with the downregulation of ki67, p65 and upregulation of PU.1.

Conclusions: Wogonin could suppress tumor growth and induce cell apoptosis by inhibiting the expression of NF-κB. Taken these findings, we concluded that wogonin could be a potential targeted therapeutic agent for EBV-positive lymphoma with the expression of LMP1 through the pathway of LMP1/NF-κB/miR-155/PU.1.

Keywords: Apoptosis, EBV infection, Lymphoma, NF-κB, Wogonin

Background

In 2015, 80900 cases were newly diagnosed with lymphoma, accounting about 5% among all cases diagnosed with tumors. The mortality of lymphoma increased consistently during the last years [1]. Epstein-Barr virus (EBV), known as an oncogenic human herpes virus, is responsible for the pathogenesis of Burkitt’s lymphoma (BL), Hodgkin lymphoma (HL), extranodal NK/T cell lymphoma and parts of diffuse large B cell lymphoma (DLBCL) [2–4]. EBV-related oncogenesis is primarily associated with latency as well as some small noncoding RNAs, such as EBV-encoded small RNAs (EBERs) and microRNAs (miRs) [5, 6]. The expression of nuclear antigens and latent membrane proteins principally induce the proliferation of B cells [7, 8]. In addition, 25 viral pre-miRs are expressed during the latent infection of EBV. They regulate the expressions of the relevant cellular miRs such as miR-155, which has been recognized as a potential oncogene in activated B-cell (ABC) lymphomas, through the NF-κB pathway [6, 9].

Researches have indicated that the infection of EBV is an aggressive course for both elderly and young patients with lymphoma [10, 11]. Conventional CHOP regimens (Adriamycin, Vincristine, Cyclophosphamide, Prednisone) lead to a poor outcome with overall survival around 14 months [12]. For CD20-positive B-cell neoplasms, the addition of Rituximab can improve the outcomes of these
patients [13], but in a small series of cases, patients with type III latency die within only 1 year even treated with Rituximab [14, 15]. Another promising novel therapy for EBV-positive B cell lymphoma is Bortezomib, a proteasome inhibitor, which has shown anti-tumor effect by inhibiting nuclear factor-κB (NF-κB) activity both in vitro and in vivo [16, 17]. Unfortunately, severe immunosuppression and myelosuppression are the main limitations preventing the wide clinical use of Rituximab and Bortezomib. Hence, new drugs with good tolerance and efficacy are highly demanded.

During the past two decades, wogonin (5, 7-dihydroxy-8-methoxylavone) has been identified as a potent apoptotic inducer for cancer cells with minor side effects [18, 19]. Wogonin is extracted from Scutellaria baicalensis Georgi (Huangqin), a perennial labiatae, and its molecular formula is C_{16}H_{12}O_{5} (Fig. 1a). Several studies have shown its inhibitory activity on tumor cells growth through intrinsic mitochondria-mediated and extrinsic receptor-mediated pathways [20, 21]. Furthermore, the inhabitation of NF-κB by wogonin also plays an important role in cell proliferation [22, 23]. Thereby, wogonin largely contributes to prevent the cellular immortalization and tumorigenesis.

Here, we assess the effect of wogonin on inducing the apoptosis of EBV (+) lymphoma cells and inhibiting tumor growth of xenografted models. This involves the exploration of the possible molecular mechanisms and pathways through which wogonin exerts its action in this cell line.

**Methods**

**Cell culture and Reagents**

The human cell line Raji (ATCC® CCL-86™), a B lymphoma cell line with EBV (+), was obtained from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). The cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Sijiqing, Hangzhou, China), 100 U/mL penicillin and 100µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA) in a 95% air and 5% CO₂ atmosphere at 37 °C.

Wogonin (provided by the Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, China) was dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich), stored at -20 °C, and diluted with medium when it was planned to be used in the experiment. MiR-155 inhibitor or miR-inhibitor normal control (NC) (GenePharma) was dissolved in DEPC-treated water prior to the experiment. Their sequence was as follows: miR-155 inhibitor (5’ to 3’) ACCCCUAUCACGAUUAGCA UUAA; miR-inhibitor NC (5’ to 3’) CAGUACUUUG UGUAGUACAA. Lipofectamin2000 (GenePharma) was used for gene transfection of miR-155 inhibitor and NC according to its manufacturer’s protocols. PDTC (Beyotime, Nantong, China), used as the inhibitor of NF-κB, was dissolved in DMSO according to suggested concentration.

**Cytotoxicity assay**

Cytotoxic effect of wogonin on the proliferating cells was detected by Cell Counting Kit 8 (CCK8, Dojindo, Kumamoto, Japan). Cells were seeded onto 96-well plates at a density of 3 × 10⁴ cells/well and treated with different concentrations of wogonin (0, 12.5, 25, 50, 100, 200 µmol/L) for 24, 48 and 72 h respectively. Then we added 10 µL of CCK8 solution into each well and incubated the cells for another 3 h. The absorbance was measured by Multiskan MK3 (Thermo Scientific, Shanghai, China) at 450 nm. After that, we calculated the cell viability as a percentage of the viable cells in the wogonin-treated group compared with the untreated control.

**Immunofluorescent staining**

Cells were dripped on glass slides, fixed with 4% paraformaldehyde, for 30 min at room temperature. Then the cell nucleus was stained with DAPI (4, 6-diamidino-2-phenylindole) (Beyotime, Haimen, China) for 5 min and was photographed with a fluorescence confocal microscope (FV-1000, Olympus, Tokyo, Japan). Between each step, the cells were washed three times with PBS.

**Flow cytometry**

Cells apoptotic rate was detected by Flow cytometry using Annexin V-FITC Apoptosis Detection Kit (Key-GEN, Nanjing, China) according to the manufacturer’s instructions. Two mL suspension of 10⁶ cells was stained with (Annexin-V-FITC and PI) kit solution in dark for 15 min. The assay then performed using FACSCalibur Flow Cytometry (BD, USA) at 488 nm.

The rate of cells cycle arrest was also detected by Flow cytometry using Cell Cycle Detection Kit (Key-GEN, Nanjing, China). Following its manufacturer’s instructions, 2 mL suspension of 10⁶ cells was fixed with 70%
ethanol, and washed by PBS before staining. The assay performed in FACSCalibur Flow Cytometry (BD, USA) at 488 nm.

**RNA extraction and qRT-PCR assay**

Total RNA was isolated from cells of each group using RNAiso Plus (TaKaRa, Dalian, China). Reverse transcription (RT) was performed with PrimeScript RT reagent kit with gDNA Eraser Kit (TaKaRa, Dalian, China), while real-time PCR was carried out using FastStart Universal SYBR Green Master (ROX) Kit (Roche, Shanghai, China) according to manufacturer’s instructions on an ABI Prism 7500 HT device (Applied Biosystems). RT of total RNA of miR-155 and its cDNA synthesis were analyzed separately using different procedures. The RT contained: Total RNA 200ng, RT primer (10μmol/L) 0.2μL, 5 × Primescript buffer 4μL, Primescript RTase 0.5μL, dNTPs 2μL, Inhibitor (20U/μL) 0.5μL and DEPC-treated water to the total of 20μL. The program was 16 °C for 30min, 42 °C for 30min, 70 °C for 15min and 4 °C for 10min. The real-time PCR contained: Premix EX Tag 10μL, Primer (20U/μL) 0.5μL, Universal reverse primer (10μmol/L) 0.5μL, ROX II 0.4μL, Sybrgreen 1μL, 5 × Primescript buffer 4μL, Universal reverse primer (10μmol/L) 0.5μL, ROX II 0.4μL, Sybrgreen 1μL, cDNA 2μL and DEPC-treated water to the total of 20μL. The program was 95 °C for 30s, and then followed by 40 cycles of 95 °C for 5s and 60 °C for 34s.

The relative expression level of mRNAs was normalized to that of internal control U6 for miR-155, while GAPDH for 5s and 60 °C for 34s.

**Dual-luciferase reporter assay**

Raji cells were seeded in 24-well plates at 5×10^5/ml overnight. Then cells were transfected with 667ng of pNFκB-ATA-luc reporter plasmid (Beyotime, Nanjing, China) and 133ng renilla luciferase-expressing plasmid as an internal control using Lipo2000 according to the manufacturer’s instructions for 24 h. After that, we set up three groups of cells, negative control group, positive control group (LPS was used as NF-κB activator) and test groups which were treated with wogonin at the concentration varying from 0μmol/L to 100μmol/L for 48h before harvesting. Firefly luciferase and renilla luciferase activities were analyzed by Dual luciferase reporter assay kit (Beyotime, Nanjing, China). Renilla luciferase activities were used as an internal control.

**Electrophoresis mobility shift assay (EMSA)**

Nuclear extracts from cells were performed with EMSA Detection Kit (Key-GEN, Nanjing, China) according to the manufacturer’s instructions. The NF-κB oligonucleotide comprised the sequence 5’-AGCTATGGGGTTCCTCCATGAGC-3’. To confirm the specificity of NF-κB, a 50-fold excess of NF-κB oligonucleotide, which was unlabeled, was added to the reaction mixture as a competitor. For EMSA, proteins were incubated with a NF-κB-specific 32p-labeled oligonucleotide and mix for binding. For supershift assay, antibodies were preincubated to the sample of interest prior to incubation with radiolabeled probe. The complexes formed were analyzed using Phosphor Imager Technology.

**Western blot analysis**

Protein was extracted from cells and blots were incubated with diluted primary antibodies LMP1 (Abcam, UK), PU.1, p65 and phospho-p65 (Santa Cruz, USA) for overnight respectively at 4°C, and then incubated with horseradish peroxidase-conjugated goat anti-rabbit or mouse secondary antibody (Santa Cruz, USA) for 2h at room temperature. GAPDH (Santa Cruz, USA) was used as the internal control. For quantity, images were analyzed using Image J software (Bethesda, MD, USA).

**Mouse xenograft model**

Four-week-old male BALB/c nude mice, 18–22 g, were purchased from Shanghai National Center for Laboratory Animals (Shanghai, China) and maintained in a pathogen-free environment. All the studies were performed in adherence with the Guidelines established by National Science Council, People of Republic of China. After the mice were injected with 1 × 10^7 cells subcutaneously, tumor volume was measured every other day and calculated. The formula was $V = \frac{a^2b}{2}$, in which "a" represented the smallest superficial diameter and "b" represented the largest superficial diameter. When the tumor volume reached nearly 50 mm^3, the mice (n = 5/group) were randomly assigned into two groups: control group and wogonin-treated group (8mg/kg per 2 days). Then the drug was administered via intraperitoneal injection every other day for 2 weeks. After 14 days, the mice were sacrificed and the tumors were removed and measured.

---

Table 1 Sequence of each primer

| Primer         | Sequence                      |
|---------------|-------------------------------|
| LMP1 (forward)| 5'-TGACCAAGGGTGTATCATC-3'    |
| LMP1 (reverse)| 5'-CATTTCTTGTCTTATGC-3'      |
| PU.1 (forward)| 5'-TCAGTCAGGCTTCTTC-3'       |
| PU.1 (reverse)| 5'-CCAACCCATGGTCTTC-3'       |
| Hsa-mir155-5p (forward)| 5'-GCGTATTATTGTGAGT-3'        |
| Hsa-mir155-5p (reverse)| 5'-GCGTATTATTGTGAGT-3'               |
| GAPDH (forward)| 5'-GCTCTGCTGCTGGAGAAT-3'     |
| GAPDH (reverse)| 5'-ACAGTCGCTTCTGAGT-3'        |
| U6 (forward)| 5'-CTCGTGCAGCGACACA-3'       |
| U6 (reverse)| 5'-AACGTTCAAGAATTTTGC-3'     |
Immunohistochemistry

UltraSensitive S-P IHC Kit (Maixin, Fuzhou, China) was used for immunohistochemical staining according to the manufacturer’s protocols. The sections were incubated with anti-p65, anti-PU.1 and anti-ki67 (1:100, Santa Cruz, USA) at 4 °C overnight. Then they were stained by a streptavidin-peroxidase system and the signal was visualized using diaminobenzidine substrate. Then the counterstaining with hematoxylin was performed to measure the microvessel density and the levels of PU.1 and ki67 by Image-Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD, USA).

Statistical analysis

All the values were shown as mean ± standard deviation (SD) from triplicate experiments performed in a parallel manner unless otherwise indicated. Data from the results was analyzed using an unpaired, two-tailed Student’s test. The level of significance was indicated as *$P < 0.05$ and **$P < 0.01$.

Results

Wogonin in vitro cytotoxicity study

In order to explore the potential anti-proliferative effects of wogonin on lymphoma cells, Raji was treated with wogonin at various concentrations (12.5–200 μmol/L) for 24 h, 48 h and 72 h respectively. A CCK8 assay was used to determine its proliferation, which showed that wogonin had the anti-proliferative effects on Raji cells in a dose- and time-dependent manner (Fig. 1b, Additional file 1: Table S1).

Wogonin induces the apoptosis of Raji cells arrested at G1 phase

The morphological changes in the nucleolus caused by apoptosis of the cells were observed under a fluorescence microscope. Raji cells that were untreated with wogonin exhibited a pale blue fluorescence, whereas those treated with wogonin exhibited a nuclear fragmentation in the apoptotic cells at the concentration between 0 and 200 μmol/L of wogonin (Fig. 2a). The following Annexin V/PI double-
staining assay also provided evidence that the percentage of apoptotic Raji cells increased after treated with wogonin from 12.5 μmol/L to 200 μmol/L in a dose-dependent manner (Fig. 2b). Furthermore, the Raji cells, which were incubated with 50μmol/L wogonin for 48 h were investigated by flow cytometry for cell cycle arrest (Fig. 2c). The difference between the percentage of S, G1 and G2 phase respectively in the control and wogonin-treated group was statically significant (Fig. 2d).

MiR-155 plays a role in the apoptosis of Raji cells

To assess whether endogenous miR-155 played a role in regulating the proliferation of EBV (+) B lymphoma cells, Raji cells were transfected with either miR-155 inhibitor at suggested concentrations (0, 50, 100, 200nmol/L) or NC for miR-155 inhibitor from the illustration of the inhibitor using Lipo2000 for 48 h. qRT-PCR was used to evaluate the mRNA expression of miR-155 of each group. The results indicated that miR-155 inhibitor could down-regulate the expression of miR-155 in Raji cells, especially at the concentration of 100 nmol/L (Fig. 3a, Additional file 2: Table S2a). Meanwhile, when the expression of miR-155 was decreased, apoptosis started in Raji cells (Fig. 3b), which accounted for 12.94 ± 4.59% of the total and was significant compared with the control group.

Moreover, the expression of LMP1 and PU.1 in Raji cells were detected by qRT-PCR (Fig. 3c, Additional file 2: Table S2b and c) and Western blot (Fig. 3d and e). The results indicated that both of the transcription and translation of PU.1 were increased in the inhibitor treated group compared with the control group, while the expression of LMP1 had no difference between the two groups.

Wogonin regulates the expression of miR-155 by NF-κB

Firstly, we used NF-κB inhibitor (PDTC), to confirm whether or not the suppression of NF-κB could also induce the apoptosis of Raji cells. The results utilized by FCM were shown in Fig. 4a. Then the expressions of LMP1, miR-155 and PU.1 were evaluated using Real Time-qPCR in the control, PDTC, wogonin and PDTC + wogonin treated groups. Three important points could be concluded from the results: 1) although the expression of LMP1 did not
show any difference among these groups, the expression of miR-155 was down-regulated significantly and on contrast the expression of PU.1 was increased after treated with PDTC or wogonin or their combination; 2) Wogonin could decrease the expression of miR-155 and increase the expression of PU.1 just like PDTC did; 3) the combination of the two drugs did not have an increased effect on these molecules compared with PDTC only (Fig. 4b, Additional file 3: Table S3). The protein level of LMP1 and PU.1 was evaluated by Western blot (Fig. 4c and d). For quantity of (c), images were analyzed using Image J. Bars were the mean ± SD (n = 3). e Effect of wogonin on the NF-κB transcriptional activation was evaluated by Dual-luciferase reporter assay in wogonin-treated Raji cells. The comparisons were made relative to control group, and the difference levels of significance was indicated as (*P < 0.05 and **P < 0.01).

Wogonin inhibits the growth of transplantable tumors and down-regulates protein level of p65 and PU.1
Tumor xenografts transplanted by Raji cells were used to evaluate the anti-tumor effect of wogonin in BALB/c nude mice in vivo. After intraperitoneal injection of wogonin every other day for 2 weeks, the tumors were moved and photographed (Fig. 6a). The average tumor size of control group was 663.4 ± 259.6 mm³, while that of wogonin treated groups was 199 ± 105.2 mm³ (Fig. 6b, Additional file 4: Table S4a). The average tumor weight of the control group was 0.426 ± 0.164 g, while that of wogonin treated groups was 0.162 ± 0.068 g (Fig. 6c, Additional file 4: Table S4b). The difference was obviously significant between the two groups.

The results indicated that wogonin had a dramatic effect on the inhibition of tumor growth. Moreover, wogonin treatment had very minor effects on the body weight of mice (Fig. 6d, Additional file 4: Table S4b), demonstrating that the maximal dose of wogonin (8 mg/kg per 2 days) had minimal toxic effects for mice.

To investigate the macroscopic observations and address the potential effect of wogonin in vivo, immunohistochemistry was performed. The results showed that ki67, the marker of tumor proliferation, was
reduced by wogonin, as well as the component of NF-κB, p65. In addition, PU.1, a protein which had been recognized as the target of miR-155 which played an important role in cell apoptosis, was increased after wogonin treatment suggesting that wogonin could attenuate tumor growth (Fig. 7).

**Discussion**

Since EBV (+) lymphoma is associated with poor prognosis [11], new therapeutic strategies are needed to improve the efficacy and reduce the toxicity of standard approaches. Potential new therapies include cellular immunotherapy, anti-viral treatments against EBV, monoclonal antibodies and inhibition of specific signaling targets [4, 24]. The cellular immunotherapy and anti-virus treatments belong to the approaches that target EBV-infected cells directly. The use of ex vivo-activated EBV-specific cytotoxic T cell lymphocytes (EBV-CTLs) and chimeric antigen receptor T-cells already had a certain curative effect on parts of EBV-related lymphomas [25–27]. However, the complex technologies and high costs limit the use of these therapies, despite of their very promising efficacy. On the other hand, EBV (+) lymphoma is not sensitive to anti-viral therapies because of lacking of EBV thymidine kinase, which is required for anti-viral activity. Therefore, histone deacetylase inhibitor, which is able to induce the lytic phase in EBV-infected lymphocytes, is usually used with Ganciclovir to improve the treatment of such disorders [28, 29]. Besides the use of anti-CD20
Fig. 6 Wogonin inhibited tumor growth in a xenografts mouse model. a The BALB/c nude mice were injected with Raji cells for a few days followed by treatment with solvent or various doses of wogonin every other day for 14 days. Then, the mice were killed, tumor removed and photographed. b, c, d The tumor size, tumor weight and body weight measurements. Bars are shown as mean ± SD (n = 5). The comparisons were made relative to untreated controls, and the difference level of significance was indicated as (*P < 0.05).

Fig. 7 Wogonin inhibited tumor proliferation by regulating the expression of p65 and PU.1 in Raji xenografts mouse model. a Immunohistochemistry was performed in tumor sections with antibodies of ki-67, p65 and PU.1. The result showed a remarkable decrease in expression of ki-67 and p65, while an increase in expression of PU.1 in the wogonin treated groups with 8mg/kg compared with untreated control groups. b, c The images were quantified using Image Pro Plus. Mean optical densities and positive area of total area of ki-67, p65 and PU.1 were shown. Bars are the mean ± SD (n = 10). The comparisons were made relative to untreated controls (100% of control), and the difference level of significance was indicated as (**P < 0.01). # The expression of PU.1 had not been detected.
antibodies such as Rituximab, Brentuximab Vedotin is now used in relapsed or refractory lymphomas as an anti-CD30 antibody [30–33]. Notably, these monoclonal antibodies have a high safety profile in patients with immunodeficiency. Furthermore, suppression of the specific signaling pathways seems to be a conventional but always effective method to prevent pathological cells from proliferating malignantly. Scientists are constantly devoting themselves to discover new inhibitors. Currently, programmed cell death ligands attract lots of attention as an immune checkpoint blockage [34]. Meanwhile, traditional Chinese medicines (represented by wogonin) are trying to establish their own position as an anti-tumor reagent in a new era.

The current studies are relevant to explore a drug with high efficacy and low toxicity for the treatment of EBV (+) lymphoma, such as BL and EBV (+) DLBCL who usually have latency III type of EBV infection and high expressions of LMP1. LMP1 is consisted of six transmembrane proteins that are able to activate the two cytoplasmic signaling molecules namely C-terminal activator regions1 and 2 (CTAR1 and 2) constitutively to transform the properties from the extracellular region to the intracellular region [35, 36]. Then, the signaling domains go through tumor necrosis factor receptor (TNFR)-associated factors (TRA6s), especially TNFR6, to activate NF-κB, making p65 free from NF-κB complex [37, 38]. After p65 binding on the miR-155 promoter in the nucleus, miR-155 begin to be vastly produced [6, 39], leading to the down-expression of its target, which is named as transcription factor PU.1, and reducing the suppressive effect of PU.1 to the apoptotic relevant protein Bcl-2 (Fig. 8) [40, 41]. As this pathway has the capacity to keep B cells immortal, the inhibition of any molecule involved in this pathway will contribute to induce apoptosis of these pathological cells. Interestingly, in our studies, the results appeared to show a close relationship between LMP1 (+) cells and wogonin. Further exploration provided the evidence that miR-155 expressed highly in Raji cells, which could be down-regulated by wogonin. Thus, it was concluded that the LMP1 and miR-155 might have potential functions in LMP1 (+) lymphoma. In fact, some studies have focused on the role of wogonin on NF-κB in the process of inflammation [42, 43]. To access whether NF-κB could be inhibited by wogonin correlated with the suppression of miR-155, we compared the expression of NF-κB,

![Diagram of the molecular mechanism of wogonin on LMP1/NF-κB/miRNA-155/PU.1 pathway.](image-url)
p65, pp65 and miR-155 of wogonin-treated group with control group and access the effect of wogonin on NF-κB activity to confirm that wogonin down-regulated miR-155 by modulating NF-κB. Although it is not the first time to report the effect of wogonin on NF-κB, it has not been reported elsewhere that wogonin can induce the apoptosis of EBV (+) lymphoma cells by LMP1/NF-κB/miR-155/PU.1 signal pathway, suggesting wogonin as a promising drug to be used in the clinic for LMP1 (+) lymphoma in the future.

Conclusions

In summary, we conclude that wogonin down-regulates the expression of NF-κB in Raji cells. The inhibition of NF-κB is associated with LMP1/NF-κB/miR-155/PU.1 pathway, suggesting the ability of wogonin to suppress the growth and induce the apoptosis of human LMP1 (+) lymphomas. Taken together, it was not only evidenced that wogonin could be a novel potential drug for LMP1 (+) lymphoma, but also implied that the detection of LMP1 should be considered for diagnosis. Therefore, our further studies will focus on the anti-tumor effect of wogonin on more EBV (+) lymphoma cell lines with LMP1 or LMP2 to identify the role of wogonin on EBV (+) lymphoma. In addition, the prognosis of patients with LMP1 (+) or (-) should be analyzed for the preparation of its use as a marker of therapy in clinics.

Additional files

Additional file 1: Table S1. The inhibitory effect of Wogonin on Raji cells at different treatment times which is shown in Fig. 1. (DOC 35 kb)

Additional file 2: Table S2. Ct values of gene expression assessed by quantitative PCR in Raji cells after inhibition of miR-155. (DOC 25 kb)

Additional file 3: Table S3. Ct values of gene expression assessed by quantitative PCR in Raji cells after inhibition of NF-κB. (DOC 21 kb)

Additional file 4: Table S4. The volume, body weight and tumor weight of mouse. (DOC 38 kb)

Acknowledgment

The authors thank China Pharmaceutical University for wogonin.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81370573), the Key Medical Subjects of Jiangsu Province (Grant No. BL2014078), and the Key Discipline of Jiangsu Province (2011-2015).

Availability of data and materials

All datasets supporting the conclusions of this article are included within the main manuscript.

Authors' contributions

XW contributed to analysis and interpretation of data and drafting of the manuscript. PL and YL contributed to acquisition of data and technical support. HZ and JS contributed to technical support and revised the manuscript for important intellectual content. FW contributed to technical support. KY contributed to technical support and analysis and interpretation of data. RF and ZC contributed to acquisition of data. BC contributed to technical support. KY contributed to technical support and analysis and interpretation of data and drafting of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors have no conflict of interest.

Consent for publication

Not applicable.

Ethics approval

Animal studies received specific ethical institutional committee approval from Southeast University Laboratory Animal Centre according to the Guidelines established by National Science Council, People of Republic of China. The cell line used in this study was obtained from other investigator under MTA agreement; no clinical specimens or human subjects were employed.

Author details

1Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Medical School, the Affiliated Zhongda Hospital, Southeast University, Nanjing 210009, China. 2Department of Gastroenterology, Medical School, The Second Hospital of Nanjing Affiliated to Southeast University, Nanjing, China. 3State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China. 4State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, China.

Received: 1 June 2016 Accepted: 15 February 2017
Published online: 21 February 2017

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5–29.
2. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1(7335):702–3.
3. Weiss LM, Movahed LA, Warneke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin’s disease. N Engl J Med. 1989; 320(8):502–6.
4. Battle-Lopez A, Gonzalez de Villambrosia S, Nuñez J, Cagigal ML, Montes-Moreno S, Conde E, Priis MA. Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options. Expert Rev Anticancer Ther. 2016;16(4):411–21.
5. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22(33):5108–21.
6. Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res. 2008;36(20):6608–19.
7. Kikuchi K, Noguchi Y, de Rivera MW, Hoshino M, Sakashita H, Yamada T, Inoue H, Miyazaki Y, Nozaki T, Gonzalez-Lopez BS, Ide F, Kusama K. Detection of Epstein-Barr virus genome and latent infection gene expression in normal epithelia, epithelial dysplasia, and squamous cell carcinoma of the oral cavity. Tumour Biol. 2016;37(3):3389–404.
8. Tang Y, Lu S, Gan X, Liu F, Zhang Y, Luo C, Pan Y, Hong L, Gan R. Expression of LMP and EBNA genes in Epstein-Barr virus-associated lymphomas in Hu-PBL/SCID mice. Oncol Rep. 2016;35(2):2905–11.
9. Gao L, Ai J, Xie Z, Zhou C, Liu C, Zhang H, Shen K. Dynamic expression of viral and cellular microRNAs in infectious mononucleosis caused by primary Epstein-Barr virus infection in children. Virus J. 2015;12:208.
10. Lu T, Liang J, Miao Y, Fan L, Wang L, Qu XY, Cao L, Gong QX, Wang Z. Zhang ZH, Xu W, Li JY. Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Sci Rep. 2015:5:12168.
11. Tisi MC, Cupelli E, Santangelo R, Maiolo E, Alma E, Giachella M, Martinii M, Bellesi S, D’Alò F, Voso MT, Pompili M, Leone G, Larocca LM, Hohaus S.
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(3):628–34.

12. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist. 2010;15(3):293–9.

13. Feuquier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferré C, Christian B, Lapage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–26.

14. Sato A, Nakamura N, Kojima M, Ohmachi K, Carreras J, Kikuti YY, Numata H, Askin M, Levy A, Mentzer SJ, Di Nicola M, Klein C, Horwitz S, Faller DV. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007; 109(6):2571–8.

15. Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol. 2007;81(18):10029–36.

16. Hao L, Han S, Zhang T, Zhang J, Wang S, Hou J. Screening active compounds acting on the epidermal growth factor receptor from Radix scutellariae via cell membrane chromotography online coupled with HPLC/MS. J Pharm Biomed Anal. 2012;62:196–202.

17. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2013;332(2):304–12.

18. Zhao L, Chen Z, Zhao Q, Wang D, Hu R, You Q, Guo Q. Developmental toxicity and genotoxicity studies of wogonin. Regul Toxicol Pharmacol. 2011;60(2):212–7.

19. Peng J, Qi Q, You Q, Hu R, Liu W, Feng F, Wang G, Guo Q. Subchronic toxicity and plasma pharmacokinetic studies on wogonin, a natural flavonoid, in Beagle dogs. J Ethnopharmacol. 2009;124(2):257–62.

20. He H, Han S, Zhang T, Zhang J, Wang S, Hou J. Screening active compounds acting on the epidermal growth factor receptor from Radix scutellariae via cell membrane chromatography online coupled with HPLC/MS. J Pharm Biomed Anal. 2012;62:196–202.

21. Yu S, Feng Y, Le Sage G, Zhang Y, Stuart C, He L, Li Y, Caffey P, Peng Y. In D. Chronic morphine-induced microRNA-124 promotes microglial immunosuppression by modulating p53 and TRAF6. J Immunol. 2015;194(3):1021–30.

22. Chen R. Results of a pivotal phase II study of brentuximab vedotin for relapsed or refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–402.

23. Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous J, Shustov AR, Smith SE, Zain J, O’Meara MA, Fanning MA. Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leuk Lymphoma. 2014;55(10):2328–34.

24. Geng L, Wang X. Epstein-Barr Virus-associated lymphoproliferative disorders: epidemiologic and clinical developments. Int J Clin Exp Med. 2015;8(9):14656–71.

25. Bollard CM, Gottschalk S, Torrano V, Diouf O, Ku S, Hazrat Y, Carrum G, Butera JN, Mentzer SJ, Di Nicola M, Klein C, Horwitz S, Faller DV. Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007; 109(6):2571–8.

26. Askin M, Levy A, Mentzer SJ, Di Nicola M, Klein C, Horwitz S, Faller DV. Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007; 109(6):2571–8.

27. Perrine SP, Hermine O, Small T, Suarez F, O’Reilly R, Boulad F, Fingerroth J, Askln M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV. Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007; 109(6):2571–8.